drug
(canagliflozin + metformin hydrochloride ER)
Marketedupdated 5mo agoby Johnson & Johnson Innovative Medicine
Approvedcommunity read0 votes
indications
investigational
Type 2 Diabetes
all catalysts(0)
nothing on the calendar yet
Patent cliff
source: FDA Orange Bookfirst barrier falls
Jul 14, 2027
284 days
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (52)
- Jul 6, 2030formulationUS 115768943.8y
- Jul 6, 2030formulationUS 115768943.8y
- Jul 6, 2030formulationUS 115768943.8y
- Jul 6, 2030formulationUS 115768943.8y
- Aug 26, 2029patentUS 7943582*PED2.9y
- Aug 26, 2029patentUS 7943582*PED2.9y
- Aug 26, 2029patentUS 7943582*PED2.9y
- Aug 26, 2029patentUS 7943582*PED2.9y
- Aug 26, 2029patentUS 7943582*PED2.9y
- Aug 26, 2029patentUS 7943582*PED2.9y
- Aug 26, 2029patentUS 7943582*PED2.9y
- Aug 26, 2029patentUS 7943582*PED2.9y
- Feb 26, 2029compositionUS 79435822.4y
- Feb 26, 2029compositionUS 79435822.4y
- Feb 26, 2029compositionUS 79435822.4y
- Feb 26, 2029compositionUS 79435822.4y
- Feb 26, 2029compositionUS 79435822.4y
- Feb 26, 2029compositionUS 79435822.4y
- Feb 26, 2029compositionUS 79435822.4y
- Feb 26, 2029compositionUS 79435822.4y
- Jun 3, 2028patentUS 8513202*PED1.7y
- Jun 3, 2028patentUS 8513202*PED1.7y
- Jun 3, 2028patentUS 8513202*PED1.7y
- Jun 3, 2028patentUS 8513202*PED1.7y
- Jun 3, 2028patentUS 8513202*PED1.7y
- Jun 3, 2028patentUS 8513202*PED1.7y
- Jun 3, 2028patentUS 8513202*PED1.7y
- Jun 3, 2028patentUS 8513202*PED1.7y
- Jan 14, 2028patentUS 7943788*PED1.3y
- Jan 14, 2028patentUS 7943788*PED1.3y
- Jan 14, 2028patentUS 7943788*PED1.3y
- Jan 14, 2028patentUS 7943788*PED1.3y
- Jan 14, 2028patentUS 7943788*PED1.3y
- Jan 14, 2028patentUS 7943788*PED1.3y
- Jan 14, 2028patentUS 7943788*PED1.3y
- Jan 14, 2028patentUS 7943788*PED1.3y
- Dec 3, 2027compositionUS 85132021.2y
- Dec 3, 2027compositionUS 85132021.2y
- Dec 3, 2027compositionUS 85132021.2y
- Dec 3, 2027compositionUS 85132021.2y
- Dec 3, 2027compositionUS 85132021.2y
- Dec 3, 2027compositionUS 85132021.2y
- Dec 3, 2027compositionUS 85132021.2y
- Dec 3, 2027compositionUS 85132021.2y
- Jul 14, 2027compositionUS 7943788284d
- Jul 14, 2027compositionUS 7943788284d
- Jul 14, 2027compositionUS 7943788284d
- Jul 14, 2027compositionUS 7943788284d
- Jul 14, 2027compositionUS 7943788284d
- Jul 14, 2027compositionUS 7943788284d
- Jul 14, 2027compositionUS 7943788284d
- Jul 14, 2027compositionUS 7943788284d
FDA exclusivities (16)
- Jun 18, 2028PEDPediatric (6mo bonus)1.7y
- Jun 18, 2028PEDPediatric (6mo bonus)1.7y
- Jun 18, 2028PEDPediatric (6mo bonus)1.7y
- Jun 18, 2028PEDPediatric (6mo bonus)1.7y
- Jun 18, 2028PEDPediatric (6mo bonus)1.7y
- Jun 18, 2028PEDPediatric (6mo bonus)1.7y
- Jun 18, 2028PEDPediatric (6mo bonus)1.7y
- Jun 18, 2028PEDPediatric (6mo bonus)1.7y
- Dec 18, 2027NPPNew Product (3y)1.2y
- Dec 18, 2027NPPNew Product (3y)1.2y
- Dec 18, 2027NPPNew Product (3y)1.2y
- Dec 18, 2027NPPNew Product (3y)1.2y
- Dec 18, 2027NPPNew Product (3y)1.2y
- Dec 18, 2027NPPNew Product (3y)1.2y
- Dec 18, 2027NPPNew Product (3y)1.2y
- Dec 18, 2027NPPNew Product (3y)1.2y
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 4h ago
Found something off?
comments(0)
5-min edit window · permanent after that